Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

Cited In for PubMed (Select 21199653)

1.

A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection.

Naik GS, Tyagi MG.

J Clin Exp Hepatol. 2012 Mar;2(1):42-54. doi: 10.1016/S0973-6883(12)60090-5. Epub 2012 Apr 12. Review.

2.

Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection.

Wu LS, Rower JE, Burton JR Jr, Anderson PL, Hammond KP, Baouchi-Mokrane F, Everson GT, Urban TJ, D'Argenio DZ, Kiser JJ.

Antimicrob Agents Chemother. 2015 Apr;59(4):2179-88. doi: 10.1128/AAC.04618-14. Epub 2015 Feb 2.

PMID:
25645847
3.

Pharmacogenomics of antimicrobial agents.

Aung AK, Haas DW, Hulgan T, Phillips EJ.

Pharmacogenomics. 2014;15(15):1903-30. doi: 10.2217/pgs.14.147.

PMID:
25495412
4.

Association between IPTA gene polymorphisms and hematological abnormalities in hepatitis C virus-infected patients receiving combination therapy.

Hwang JJ, Lo CC, Lin CH, Cheng HS, Hung IW, Tsai WJ, Hung CH.

Gut Liver. 2015 Mar;9(2):214-23. doi: 10.5009/gnl14095.

5.

Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir.

Aghemo A, Grassi E, Rumi MG, D'Ambrosio R, Galmozzi E, Degasperi E, Castaldi D, Soffredini R, Colombo M.

PLoS One. 2014 Apr 23;9(4):e95881. doi: 10.1371/journal.pone.0095881. eCollection 2014.

6.

Individualization of chronic hepatitis C treatment according to the host characteristics.

Gatselis NK, Zachou K, Saitis A, Samara M, Dalekos GN.

World J Gastroenterol. 2014 Mar 21;20(11):2839-53. doi: 10.3748/wjg.v20.i11.2839. Review.

7.

Purinergic signalling in the liver in health and disease.

Burnstock G, Vaughn B, Robson SC.

Purinergic Signal. 2014 Mar;10(1):51-70. doi: 10.1007/s11302-013-9398-8. Epub 2013 Nov 24. Review.

8.

Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy.

Crismale JF, Martel-Laferrière V, Bichoupan K, Schonfeld E, Pappas A, Wyatt C, Odin JA, Liu LU, Schiano TD, Perumalswami PV, Bansal M, Dieterich DT, Branch AD.

Liver Int. 2014 Aug;34(7):1018-24. doi: 10.1111/liv.12342. Epub 2013 Oct 25.

PMID:
24118693
9.

Metabolome analysis of erythrocytes from patients with chronic hepatitis C reveals the etiology of ribavirin-induced hemolysis.

Karasawa T, Saito T, Ueno Y, Sugimoto M, Soga T.

Int J Med Sci. 2013 Sep 9;10(11):1575-7. doi: 10.7150/ijms.6436. eCollection 2013.

10.

ITPA (inosine triphosphate pyrophosphatase): from surveillance of nucleotide pools to human disease and pharmacogenetics.

Simone PD, Pavlov YI, Borgstahl GE.

Mutat Res. 2013 Oct-Dec;753(2):131-46. doi: 10.1016/j.mrrev.2013.08.001. Epub 2013 Aug 19. Review.

11.

Management of anemia in patients receiving triple therapy for hepatitis C.

Barritt AS 4th.

Gastroenterol Hepatol (N Y). 2013 May;9(5):314-6. No abstract available.

12.

Association of ITPA polymorphism with outcomes of peginterferon-α plus ribavirin combination therapy.

Fujino T, Aoyagi Y, Takahashi M, Yada R, Yamamoto N, Ohishi Y, Nishiura A, Kohjima M, Yoshimoto T, Fukuizumi K, Nakashima M, Kato M, Kotoh K, Nakamuta M, Enjoji M.

World J Gastrointest Pharmacol Ther. 2013 Aug 6;4(3):54-60. doi: 10.4292/wjgpt.v4.i3.54.

13.

Leveraging prior information to detect causal variants via multi-variant regression.

Long N, Dickson SP, Maia JM, Kim HS, Zhu Q, Allen AS.

PLoS Comput Biol. 2013;9(6):e1003093. doi: 10.1371/journal.pcbi.1003093. Epub 2013 Jun 6.

14.

Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients.

Ahmed WH, Furusyo N, Zaky S, Eldin AS, Aboalam H, Ogawa E, Murata M, Hayashi J.

World J Gastroenterol. 2013 Mar 7;19(9):1387-95. doi: 10.3748/wjg.v19.i9.1387.

15.

Effect of laparoscopic splenectomy in patients with Hepatitis C and cirrhosis carrying IL28B minor genotype.

Motomura T, Shirabe K, Furusyo N, Yoshizumi T, Ikegami T, Soejima Y, Akahoshi T, Tomikawa M, Fukuhara T, Hayashi J, Maehara Y.

BMC Gastroenterol. 2012 Nov 12;12:158. doi: 10.1186/1471-230X-12-158.

16.

Modulation of mutagenesis in eukaryotes by DNA replication fork dynamics and quality of nucleotide pools.

Waisertreiger IS, Liston VG, Menezes MR, Kim HM, Lobachev KS, Stepchenkova EI, Tahirov TH, Rogozin IB, Pavlov YI.

Environ Mol Mutagen. 2012 Dec;53(9):699-724. doi: 10.1002/em.21735. Epub 2012 Oct 10. Review.

17.

Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin.

Miyamura T, Kanda T, Nakamoto S, Wu S, Jiang X, Arai M, Fujiwara K, Imazeki F, Yokosuka O.

Viruses. 2012 Aug;4(8):1264-78. Epub 2012 Aug 14.

18.

Prioritizing genetic variants for causality on the basis of preferential linkage disequilibrium.

Zhu Q, Ge D, Heinzen EL, Dickson SP, Urban TJ, Zhu M, Maia JM, He M, Zhao Q, Shianna KV, Goldstein DB.

Am J Hum Genet. 2012 Sep 7;91(3):422-34. doi: 10.1016/j.ajhg.2012.07.010. Epub 2012 Aug 30.

19.

ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV.

Osinusi A, Naggie S, Poonia S, Trippler M, Hu Z, Funk E, Schlaak J, Fishbein D, Masur H, Polis M, Kottilil S.

J Med Virol. 2012 Jul;84(7):1106-14. doi: 10.1002/jmv.23302.

20.

Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy.

Domingo P, Guardiola JM, Salazar J, Torres F, Mateo MG, Pacho C, Del Mar Gutierrez M, Lamarca K, Fontanet A, Martin J, Muñoz J, Vidal F, Baiget M.

Antimicrob Agents Chemother. 2012 Jun;56(6):2987-93. doi: 10.1128/AAC.06473-11. Epub 2012 Mar 19.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk